Floatz logo

Therapeutic Asset Ratings

6,371 results matching 1 filter

129,767 assets · 8,707 sponsors · 3,128 indications
Methodology v0.2
AssetSponsorPhaseRating
Blinatumomab
Leukemia, Lymphoblastic, Acute, Philadelphia-Positive
Novartis PharmaceuticalsP3BB (67)
Girentuximab
Nonpapillary Renal Cell Carcinoma
Massachusetts General HospitalP3BB (67)
IMMUNOGLOBULIN G1, ANTI-(HUMAN NEU (RECEPTOR)) (HUMAN-MOUSE MONOCLONAL 2C4 HEAVY CHAIN), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL 2C4 .KAPPA.-CHAIN, DIMER
Colon Adenocarcinoma
IFOM ETS - The AIRC Institute of Molecular OncologyP3BB (67)
IMMUNOGLOBULIN G1, ANTI-(HUMAN NEU (RECEPTOR)) (HUMAN-MOUSE MONOCLONAL 2C4 HEAVY CHAIN), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL 2C4 .KAPPA.-CHAIN, DIMER
Invasive Breast Carcinoma
Baylor Breast Care CenterP3BB (67)
IMMUNOGLOBULIN G1, ANTI-(HUMAN NEU (RECEPTOR)) (HUMAN-MOUSE MONOCLONAL 2C4 HEAVY CHAIN), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL 2C4 .KAPPA.-CHAIN, DIMER
HER-2 Positive Breast Cancer
National Taiwan University HospitalP3BB (67)
IMMUNOGLOBULIN G 1 (HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD 20), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .KAPPA.-CHAIN, DIMER
Chronic Myeloid Leukemia
OHSU Knight Cancer InstituteP3BB (67)
IMMUNOGLOBULIN G 1 (HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD 20), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .KAPPA.-CHAIN, DIMER
Indolent B-Cell Non-Hodgkin Lymphoma
Fox Chase Cancer CenterP3BB (67)
IMMUNOGLOBULIN G 1 (HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD 20), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .KAPPA.-CHAIN, DIMER
Nodal Marginal Zone B-Cell Lymphoma
City of Hope Medical CenterP3BB (67)
IMMUNOGLOBULIN G 1 (HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD 20), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .KAPPA.-CHAIN, DIMER
Splenic Marginal Zone Lymphoma
City of Hope Medical CenterP3BB (67)
Ipilimumab
Non-Small Cell Lung Carcinoma
University of ChicagoP3BB (67)
Ixekizumab
Psoriasis
Eli Lilly and CompanyP3BB (67)
Nivolumab
Colon Carcinoma Metastatic in the Liver
University of SaskatchewanP3BB (67)
Nivolumab
Anal Carcinoma
Instituto do Cancer do Estado de São PauloP3BB (67)
Pembrolizumab
Hematopoietic And Lymphoid System Neoplasm
Vividion Therapeutics, Inc.P3BB (67)
Pembrolizumab
Endometrial Cancer
Eli Lilly and CompanyP3BB (67)
Pembrolizumab
Germ Cell Tumor
Hoffmann-La RocheP3BB (67)
Pembrolizumab
Urethra Transitional Cell Carcinoma
Alliance for Clinical Trials in OncologyP3BB (67)
Pembrolizumab
Cutaneous Neuroendocrine Carcinoma
Merck Sharp & Dohme LLCP3BB (67)
Pembrolizumab
Metastatic Renal Pelvis Urothelial Carcinoma
Fred Hutchinson Cancer CenterP3BB (67)
Pembrolizumab
Metastatic Ureter Urothelial Carcinoma
Fred Hutchinson Cancer CenterP3BB (67)
Pembrolizumab
Metastatic Urethral Urothelial Carcinoma
Alliance for Clinical Trials in OncologyP3BB (67)
Pembrolizumab
Papillary Renal Cell Carcinoma
First Affiliated Hospital, Sun Yat-Sen UniversityP3BB (67)
Tislelizumab
Non-Small Cell Squamous Lung Carcinoma
BeOne MedicinesP3BB (67)
Tislelizumab
Classic Hodgkin Lymphoma
Children's Cancer Group, ChinaP3BB (67)
Tislelizumab
Diffuse Large B-Cell Lymphoma
Ningbo No. 1 HospitalP3BB (67)
Showing 201 to 225 of 6,371 assets
PreviousPage 9 of 255Next